Please note that due to a high volume of submissions, the ANZCTR is currently experiencing a delay in processing of submissions.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00234169




Registration number
NCT00234169
Ethics application status
Date submitted
4/10/2005
Date registered
6/10/2005
Date last updated
10/05/2012

Titles & IDs
Public title
A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone
Scientific title
A Phase I/II Study of Peripheral Blood Progenitor Cells Mobilisation With VTP195183 Plus G-CSF Compared to Mobilisation With G-CSF Alone in Patients With Multiple Myeloma and Lymphoma.
Secondary ID [1] 0 0
05/09
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - VTP195183

Treatment: Drugs: VTP195183
VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.
Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
PB CD34+ kinetics using VTP195183 plus G-CSF
Timepoint [1] 0 0
up to 28 days post study drug administration
Secondary outcome [1] 0 0
The toxicity of VTP195183 pretreatment when used with G-CSF
Timepoint [1] 0 0
within 28 days of study drug administration

Eligibility
Key inclusion criteria
1. Age 18-70

2. Histologically proven multiple myeloma or lymphoma

3. Intent of treating physician to proceed to high dose therapy and autologous
transplantation

4. Not currently receiving thalidomide (within 1 week of commencing VTP195813 or G-CSF),
cytotoxic agents or high dose prednisolone or Dexamethasone (at doses greater than 15
mg prednisolone or equivalent per day)

5. Multiple myeloma patients must be taking regular bisphosphonate therapy

6. Absolute neutrophil count between 1.5 and 10 x 109/L

7. ECOG performance status ? 2

8. Life expectancy of at least 2 months

9. Written informed consent signed by patient or legally authorized representative
Minimum age
18 Years
Maximum age
70 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Active infection or a fever > 38.2 degrees C (fever due to B symptoms in lymphoma
patients will not exclude a patient)

2. Use within the previous 30 days of other vitamin A preparations within the last 30
days (including oral vitamin supplements, oral retinoids for acne or other skin
disorders, bexarotene, or topical vitamin A preparations)

3. Pregnancy or breast feeding. Women of child-bearing potential, admitted to the trial
must take adequate measures to prevent conception (at least two different forms of
contraception during the study and for at least one month after completion of study
drugs) and are to undergo a pregnancy test

4. Significant non-malignant disease including HIV infection, uncontrolled hypertension
(diastolic blood pressures > 115 mmHg), unstable angina

5. Known allergy to E.coli-derived products

6. Current treatment with tetracycline antibiotics

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1/Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Peter MacCallum Cancer centre - Melbourne
Recruitment postcode(s) [1] 0 0
3002 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Peter MacCallum Cancer Centre, Australia
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
The Leukemia and Lymphoma Society
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Hematopoietic stem cells (HSC) are used to support the administration of high dose
chemotherapy for a range of human cancers. For a safe HSC transplantation, a minimum of 5
million HSC per kilogram are required. HSC are collected from the bone marrow by using drugs
such as G-CSF (filgrastim) which 'mobilize' them from the bone marrow into the bloodstream.
HSC are collected from the bloodstream using an apheresis machine. Between 5 and 60% of
patients fail to mobilize the minimum HSC dose required for safe transplantation, and this
trial is investigating a way to enhance mobilization to overcome this problem. This trial
aims to determine if a new vitamin A derivative is capable of enhancing HSC mobilization when
used in conjunction with G-CSF. Patients will undergo two mobilization procedures. They will
be given G-CSF alone, or a combination of the study drug plus G-CSF, and their stem cells
will be collected. A comparison group of patients will be given G-CSF alone for both
mobilizations. Stem cells collected from patients in this trial will be frozen and stored
until they are required for transplantation into that patient. At that time, patients will be
monitored for how well they recover from their high dose chemotherapy and HSC
transplantation.
Trial website
https://clinicaltrials.gov/show/NCT00234169
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Kirsten Herbert, MBBS
Address 0 0
Peter MacCallum Cancer Centre, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications